Company Overview of Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc., a biological therapeutics company, engages in the discovery, development, and commercialization of therapeutic treatments for gastrointestinal diseases and conditions. The company focuses on gastrointestinal physiology, metabolism, and gut adaptation associated with gastrointestinal diseases, including lactose intolerance, irritable bowel syndrome, crohn's disease, and ulcerative colitis. It develops RP-G28 for the treatment of lactose intolerance. The company was founded in 2004 and is based in Los Angeles, California.
1880 Century Park East
Los Angeles, CA 90067
Founded in 2004
Key Executives for Ritter Pharmaceuticals, Inc.
Chief Executive Officer and Director
Head of Operations & Corporate Development
Head of Clinical Development
Chief of Clinical and Regulatory Development
Compensation as of Fiscal Year 2014.
Ritter Pharmaceuticals, Inc. Key Developments
Ritter Pharmaceuticals, Inc. Names Michael D. Step as Chief Executive Officer, Effective October 1, 2014
Sep 30 14
Ritter Pharmaceuticals, Inc. announced that Michael D. Step has been named chief executive officer, effective October 1, 2014. Mr. Step was appointed to the company's board of directors in 2011 and will continue to serve as a director. Andrew Ritter, the company's founder, who previously served as president and chief executive officer, will now hold the title of president while continuing as a director. Mr. Step has more than 20 years of experience in the pharmaceutical industry. For the past nine years, he was senior vice president of corporate development and a member of the executive committee of Santarus, Inc. until its sale to Salix Pharmaceuticals in January 2014. In this role, Mr. Step was responsible for leading the licensing activities for the company and the culmination of more than a dozen significant transactions. Prior to Santarus, Mr. Step served as vice president of corporate development and as executive director of commercial operations for Amylin Pharmaceuticals, where he led the licensing agreement with Eli Lilly a d Company for Byetta(R) and helped plan the commercial operation structure for Symlin(R). Earlier in his career, Mr. Step served in leadership roles in business development, commercial management and sales at Dura Pharmaceuticals, Hoffmann-La Roche and Syntex Laboratories.
Ritter Pharmaceuticals, Inc. Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal
Jan 8 14
Ritter Pharmaceuticals, Inc. announced that Nutrition Journal has published the results of its phase 2 trial of RP-G28, a proprietary oligosaccharide under investigation as a potential treatment for lactose intolerance. The study manuscript entitled, 'Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial" is the first peer-reviewed presentation of the protocol, assessments and results which showed that RP-G28 dramatically reduced the pain and symptoms of lactose intolerant patients.
Ritter Pharmaceuticals, Inc. Appoints Larry Good as Chief Medical Officer; Expects to Design and Initiate its Next Phase 2 Clinical Studies of RP-G28 in Patients with Lactose Intolerance in Later 2013
Feb 13 13
Ritter Pharmaceuticals, Inc. announced the appointment of Larry I. Good, M.D., F.A.C.G. to the position of Chief Medical Officer. Dr. Good is a Fellow of the American College of Gastroenterology and has served as the Chief Physician in Gastroenterology at South Nassau Communities Hospital and Lydia E. Hall Hospital in New York. He joined Ritter Pharmaceuticals in 2012.
The company expects to design and initiate its next Phase 2 clinical studies of RP-G28 in patients with lactose intolerance later 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|